Literature DB >> 1177634

The evaluation of treatment of patients with extensive squamous cancer of the vocal cords.

R H Jesse.   

Abstract

Fifty-one patients with previously untreated squamous carcinoma originating on the true vocal cord, staged T4, were analyzed. Forty-eight of the 51 patients were selected for treatment. Total laryngectomy was the minimal surgical procedure, and the pathologist confirmed the presence of cancer outside the confines of the larynx in 47 of 48 patients. Seventy-three percent of the patients were thought clinically to have negative nodes, but examination by the pathologist showed a 20 percent false negative rate in this evaluation. Twenty-one percent of the patients had received an emergency tracheostomy prior to being referred to out institution. An additional 8 percent required an emergency tracheostomy or laryngectomy. Radiation therapy was employed postoperatively for 16 patients. Twenty-six (54 percent) of the 48 patients had no further evidence of cancer after treatment. In evaluating the failures, previous tracheostomy, extension of the disease to the pharyngeal wall, and positive cervical lymph nodes were found to effect adversely the survival of the patient; however, extension of the disease into the trachea, when it occurred alone, was not an adverse factor. In this patient group with a median age of 66 years, 27 percent died of causes other than the cancer within four years. Based on the data in this series, postoperative radiation therapy is now being routinely given to patients with disease extending to the pharyngeal wall, those with nodes in the neck, and those who have had an emergency tracheostomy previously.

Entities:  

Mesh:

Year:  1975        PMID: 1177634     DOI: 10.1288/00005537-197509000-00002

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

1.  Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey.

Authors:  David I Rosenthal; Abdallah S R Mohamed; Randal S Weber; Adam S Garden; Parag R Sevak; Merril S Kies; William H Morrison; Jan S Lewin; Adel K El-Naggar; Lawrence E Ginsberg; Esengul Kocak-Uzel; K Kian Ang; Clifton David Fuller
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

2.  mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma.

Authors:  Lijing Zhao; Bo Teng; Lianji Wen; Qingjie Feng; Hebin Wang; Na Li; Yafang Wang; Zuowen Liang
Journal:  Int J Clin Exp Med       Date:  2014-02-15

3.  Long-term outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches.

Authors:  Clifton D Fuller; Abdallah S R Mohamed; Adam S Garden; G Brandon Gunn; Collin F Mulcahy; Mark Zafereo; Jack Phan; Stephen Y Lai; Jan S Lewin; Katherine A Hutcheson; Steven J Frank; Beth M Beadle; William H Morrison; Adel K El-Naggar; Esengul Kocak-Uzel; Lawrence E Ginsberg; Merril S Kies; Randal S Weber; David I Rosenthal
Journal:  Head Neck       Date:  2016-07-28       Impact factor: 3.147

4.  Pretreatment computed tomographic gross tumor volume as predictor of persistence of tracheostomy and percutaneous endoscopic gastrostomy tube in patients undergoing larynx preservation.

Authors:  Newton J Hurst; Lucio M Pereira; Michael M Dominello; Gregory Dyson; Pamela Laszewski; Natasha Robinette; Ho-Sheng Lin; George Yoo; Ammar Sukari; Harold Kim
Journal:  Head Neck       Date:  2016-04-30       Impact factor: 3.147

5.  A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.

Authors:  J J Beitler; R V Smith; H Haynes; C E Silver; A Quish; T Kotz; M Serrano; A Brook; S Wadler
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

6.  Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.

Authors:  Maureen Bernadach; Michel Lapeyre; Anne-Françoise Dillies; Jessica Miroir; Melanie Casile; Juliette Moreau; Ioana Molnar; Angeline Ginzac; Nathalie Pham-Dang; Nicolas Saroul; Xavier Durando; Julian Biau
Journal:  BMC Cancer       Date:  2021-04-07       Impact factor: 4.430

7.  In vitro and in vivo effect of 5-FC combined gene therapy with TNF-α and CD suicide gene on human laryngeal carcinoma cell line Hep-2.

Authors:  Li-Ping Chai; Zhang-Feng Wang; Wei-Ying Liang; Lei Chen; Dan Chen; An-Xun Wang; Zhao-Qiang Zhang
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.